Zalunfiban Shows Promise at AHA Scientific Sessions
Slice of Healthcare Team
11/15/2025
Key highlights
- Zalunfiban shows efficacy in STEMI treatment
- Phase 3 trial conducted on 2,467 patients
- Quick antiplatelet effects aid emergency response
- Developed with support from Harrington Discovery Institute
- A promising advancement in cardiovascular medicine
Source: PR Newswire
Notable Quotes
“ My therapeutics development advisory team at Harrington Discovery Institute played a crucial role in where we are today. ”
Barry Coller, MD, Vice President for Medical Affairs at The Rockefeller University
“ Dr. Coller's work is an excellent example of our mission being accomplished. ”
Jonathan S. Stamler, MD, President and Co-Founder at Harrington Discovery Institute
Why this matters
The announcement of zalunfiban's positive clinical trial results represents a significant advancement in the treatment of heart attacks (STEMI), potentially transforming emergency medical protocols and improving patient outcomes in critical situations. This development is particularly significant for the healthcare sector.
